- Active not recruitingPHASE1
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
This early-stage study is testing a new drug called Tuvusertib (M1774), alone or with another drug called niraparib, for people with advanced solid tumours that have spread or can't be removed by surgery. Doctors want to see if it's safe, how the body handles it, and if it shows any early signs of helping.
For: Metastatic or Locally Advanced Unresectable Solid TumorsUnited States · China · Japan - Active not recruitingPHASE1, PHASE2
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This study is testing a new combination of two medicines, Tuvusertib and Cemiplimab, for people with a specific type of lung cancer (non-squamous NSCLC). It's for those whose cancer has grown despite previous treatments, including immunotherapy and chemotherapy.
For: Non-Small Cell Lung CancerUnited States · Belgium · France